Zhaoke Ophthalmology Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation $(ODD)$ to its proprietary formulation of melphalan for the treatment of pediatric retinoblastoma, a rare pediatric eye cancer. This designation provides a clear regulatory pathway toward the submission of an Investigational New Drug $(IND.AU)$ application in the U.S. If successfully developed and approved, Zhaoke Ophthalmology Ltd. would be eligible for seven years of market exclusivity in the U.S. upon New Drug Application (NDA) approval. This exclusivity includes marketing authorization holder status and data exclusivity, offering comprehensive protection in the market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.